Barely Significant
← all excerpts

Cost-effectiveness of Ezetimibe plus statin lipid-lowering therapy: A systematic review and meta-analysis of cost-utility studies.

PLoS One · 2022 · PMC9202874 · PMID 35709152

1
hedged sentence
closest p
boldest claim

The sentences

a clear trendno p-value reported
We could not discern a clear trend regarding whether using data from clinical trials instead of observational studies in terms of baseline risk and treatment effect improves the cost-effectiveness results.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.